Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031720 · ClinicalTrials.gov registry record · Phase 2
Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease
A Phase 2 study of Breast Cancer and Hot Flashes, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
- 14
- Study locations
NCT00031720: Completed Phase 2 study of Breast Cancer and Hot Flashes, sponsored by Alliance for Clinical Trials in Oncology.
NCT00031720 is a Phase 2 study of Breast Cancer and Hot Flashes that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 112 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 14 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00031720, a Phase 2 study of Breast Cancer and Hot Flashes, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
- 14
- Study locations
Study Summary
RATIONALE: Soy protein supplement may be effective in reducing hot flushes in postmenopausal women who are receiving tamoxifen for breast disease. PURPOSE: Randomized phase II trial to determine the effectiveness of soy protein supplement in reducing hot flushes in postmenopausal women who are receiving tamoxifen for breast disease such as ductal hyperplasia or breast cancer.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Tamoxifen
- DIETARY_SUPPLEMENT soy protein
- DIETARY_SUPPLEMENT isoflavones
Study Locations (14)
Indiana
- Elkhart General Hospital - Elkhart
- Howard Community Hospital - Kokomo
- Center for Cancer Therapy at LaPorte Hospital and Health Services - La Porte
- CCOP - Northern Indiana CR Consortium - South Bend
- Memorial Hospital of South Bend - South Bend
- Saint Joseph Regional Medical Center - South Bend
North Carolina
- Wayne Memorial Hospital, Incorporated - Goldsboro
- Kinston Medical Specialists - Kinston
- FirstHealth Moore Regional Community Hospital Comprehensive Cancer Center - Pinehurst
New Hampshire
- Kingsbury Center for Cancer Care at Cheshire Medical Center - Keene
- Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center - Lebanon
Illinois
- Center for Cancer Care at OSF Saint Anthony Medical Center - Rockford
Massachusetts
- Commonwealth Hematology-Oncology, PC - Worcester - Worcester
Michigan
- Lakeland Regional Cancer Care Center - St. Joseph - Saint Joseph
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2002-03 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
What the finished NCT00031720 record still lists
NCT00031720 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT00031720 lists 14 locations in 6 states (Indiana, North Carolina, New Hampshire).
Frequently Asked Questions
What is clinical trial NCT00031720 about?
NCT00031720 is a clinical study titled "Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease". RATIONALE: Soy protein supplement may be effective in reducing hot flushes in postmenopausal women who are receiving tamoxifen for breast disease. PURPOSE: Randomized phase II trial to determine the effectiveness of soy protein supplement in reducing hot flushes in postmenopausal women who are rece...
What is the current status of trial NCT00031720?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2002-03. Estimated completion is 2013-11.
What conditions does trial NCT00031720 study?
This clinical trial studies the following conditions: Breast Cancer, Hot Flashes, Hot Flushes.
What interventions are being tested in trial NCT00031720?
The interventions under investigation include: Placebo (OTHER), Tamoxifen (DRUG), soy protein (DIETARY_SUPPLEMENT), isoflavones (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00031720?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00031720 being conducted?
This trial has 14 study locations across Illinois, Indiana, Massachusetts, Michigan, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00031720's enrollment target sits among peer trials
112 533rd of 1224 higher than 690 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia